Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company with a custom-developed Fr8App, anindustry-leading freight-matching platform powered by AI andmachine-learning, offering a real-time portal for B2B cross-borderand domestic shipping within the USMCA region. The company todayannounced an increase in its convertible note facility by $3.3million to $9.9 million in addition to renewing its collateralizedlending facility for $5.0 million. Fr8Tech agreed to amend its loanand security agreement with Capital Foundry and extend it to 2025,with the amendment maintaining the revolving line of credit at $5.0million and including additional types of collateral in line withFr8Tech’s anticipated growth. “It has been great to see Fr8Techevolve since we first started working with them in 2019, especiallyits accelerated growth in the past eighteen months,” said John Fox,Capital Foundry’s chief credit officer. “We look forward to theresults we believe the company can achieve with this additionalliquidity to continue to support its ambitious growth plans.”

To view the full press release, visit https://ibn.fm/vfmEv

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

• Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
• Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
• Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
• Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
• Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
• Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $1.9, up 11.1111%, on 256,569 volume. The average volume for the last 3 months is 256,569 and the stock's 52-week low/high is $1.3424/$31.512.

Recent News

• Freight Technologies Inc. (NASDAQ: FRGT) - InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Secures Additional Funding to Support Growth
• Freight Technologies, Inc. Obtains and Renews Additional Funding
• InvestorNewsBreaks - Freight Technologies Inc.'s (NASDAQ: FRGT) Fr8App Named BeatBox's No. 1 Carrier for Cross Border Shipments

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

New research has found that pregnant women who take vitamin D supplements during their pregnancy considerably reduce the likelihood of theirinfant developing eczema. Eczema is a noncontagious chronic skincondition that causes an individual’s skin to become itchy and dry.While the primary cause isn’t known, the condition may be triggered by allergens or environmental factors.Vitamin D (cholecalciferol) is a fat-soluble vitamin that can be found in foods such as egg yolks and oily fish. This vitamin, which is alsoavailable as a dietary supplement, is also produced in the bodywhen UV rays from the sun trigger vitamin D synthesis. The studywas carried out by scientists at the Medical Research Council Lifecourse Epidemiology Centre, University of Southampton. For children who eventually developeczema, a number of new products from many companies such as Jupiter Wellness Inc. (NASDAQ: JUPW) can be of help in giving patients a better quality of life despitetheir diagnosis.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

• Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
• Psoriasis & Vitiligo – Photocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
• Jellyfish Protection Sunscreen – NoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
• Eczema – JW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
• Burns – JW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
• Cold Sores – JW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
• Sexual Wellness – JW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
• COVID-19-Induced Tinnitus – JW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

• Jupiter Wellness Inc. (NASDAQ: JUPW) - Research Finds Taking Vitamin D Supplements While Pregnant Reduces Eczema Risk in Infants
• InvestorNewsBreaks - Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Three New Executive Team Leaders
• NIH Research Links Eczema Onset to Air Pollution

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

New research has found that roundworms exposed to marijuanacompounds also get the munchies, just like humans. Cannabinoid molecules derived from the marijuanaplant usually bind to endocannabinoids, whose receptors are foundin the brain, other organs and connective tissues.Popular cannabinoid molecules includetetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN),cannabichromene (CBC), cannabigerol (CBG), 9-tetrahydrocannabivarin(THCV), cannabidivarin (CBDV) and cannabivarin (CBV).The endocannabinoid system is said tobalance key bodily functions and regulate functions such as eating,anxiety, memory and sleep. Plenty of research is currently ongoing,with enterprises such as IGC Pharma Inc. (NYSE American: IGC) setting their sights on having FDA-approved formulations on themarket to help patients with different ailments.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.345, up 3.5725%, on 65,964 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.8432.

Recent News

• IGC Pharma Inc. (NYSE American: IGC) - 420 with CNW - Research Finds Marijuana Gives Roundworms the Munchies
• 420 with CNW - North Carolina Legislators File Bills to Legalize Recreational Cannabis
• 420 with CNW - New York Governor Announces Campaign to Promote Purchase of Legal Cannabis

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: BMR) (OTCQB: BTRMF).

Battery Mineral Resources (TSX.V: BMR) (OTCQB: BTRMF) (“BMR”) in October announced it had filed a technical report for its NI43-101 resource estimate at Punitaqui on SEDAR. The report wasauthored by JDS Mining and Energy Inc. (“JDS”). “We are extremelypleased to have completed the very comprehensive PunitaquiTechnical Report. This report encompasses four different deposits,including Cinabrio, which is the deposit that was the main sourceof ore for the Punitaqui copper concentrator for the nine plusyears of operating history. We are very encouraged with the resultsof our drilling program but also encouraged by the opportunity wehave to continue adding resources in not only all four deposits butthroughout our significant land package of 8,693 hectares. Inaddition, the report displays the large amount of work includingengineering, permitting and metallurgy, which has been focused onboth de-risking and uncovering opportunities at this very promisingproject. Work is nearing completion to apply best practices tothese new resources with the intention of arriving at soundconclusions regarding project economics and mine life. It is thefull intention to use these conclusions to obtain the remainder offunding required for the recommencing of mine operations this year,followed closely by copper concentrate production at the Punitaquimill. On behalf of the board of directors of the company, I’d liketo thank the people at JDS as well as our team in Chile for theirhard work in accomplishing this major milestone for the company.”In addition, Battery Mineral Resources in December provided asummary of the highlights of its accomplishments in 2022. BMRdescribed a transformational year and reported several highlights,including the funding and completion of a very successful Punitaquiresource drill program, significant strengthening of its managementand board, greatly advancing its permitting and having securedimportant milestones in the process. The company views itsaccomplishments as a strong base to allow further progressiontowards cash flowing in the near term. To view the full pressreleases, visit https://ibn.fm/TvcTv and https://ibn.fm/NlZHt

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration and acquisitions in favorable mining jurisdictions.

The company’s mission is the discovery, acquisition and development of battery metals (namely copper, cobalt, lithium, and graphite) in North America, South America and South Korea. It aims to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries.

BMR is headquartered in Vancouver, British Colombia, with a portfolio of projects spanning Canada, the U.S., Chile and South Korea.

Project Portfolio

BMR’s current focus is the restart of its Punitaqui copper mine in Chile, as well as the exploration and development of its cobalt, lithium and graphite assets in North America and South Korea. The company also continues to identify and evaluate new project opportunities in its operating jurisdictions.

Its current portfolio includes:

Chile – Copper

BMR’s 100%-owned Punitaqui copper mine, acquired in March 2021, has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. The company’s flagship project, the Punitaqui mine has been the subject of numerous milestones in recent months, including:

• BMR funded and completed a successful 32,526m resource drill program in 2022. Metallurgical testwork has confirmed the ability to produce excellent copper concentrates from each of the five zones tested, including recoveries ranging from 81% on the low end at Cinabrio Norte up to 96.5% at the Dalmacia deposit.
• The company in August 2022 reported the results of its first ever NI 43-101-compliant resource estimate for the underground deposits at its Punitaqui copper mining complex of 6.2 million tonnes grading 1.14% Cu in indicated category, along with 3.1 million tonnes grading 0.93% Cu in the inferred category. This resource estimate greatly exceeded management goals.
• In September 2022, BMR announced the approval by the Chilean Environment Assessment Service for the Environmental Impact Declaration (“DIA”) pertaining to mining at the company’s Cinabrio mine and San Andres deposit. The approval of the DIA allows BMR to move forward with starting mining operations in 2023 and restarting the mill at its Punitaqui copper mining complex soon after.
• BMR is focused on securing the final funding for the restart of mining and resumption of copper concentrate production at Punitaqui. Once this funding is received, BMR aims to complete mine rehabilitation and development in four to six months, with the ramp up from first production to the full production rate of 20-25 million pounds of copper in concentrate per annum to require a further four to six months.

“From exploration, engineering, community and permitting successes to realizing several non-dilutive means of funding to allow BMR to advance the project, our team looks forward to taking advantage of the renewed positive market sentiment for near term copper pricing and placing ourselves in a strong position to participate in a robust copper sector in 2023,” CEO Martin Kostuik stated in a news release.

Canada – Cobalt/Silver

Between 2016 and April 2018, BMR acquired through claim staking, option, joint venture and direct purchase the largest regional land holding in the historic home of high-grade cobalt-silver veins in Canada known locally as the Cobalt Embayment.

As of February 2023, BMR controlled a land package totaling 9 properties with 4,086 tenements that encompass an area of 84,003.39Ha. The key projects within the land package include McAra, Gowganda, Elk Lake, Fabre and Wilder. From 2017-2022, a total of 412 holes/51,452.34m were drilled on eight projects/20 targets. In addition, a total of 26,709 Line-Km of airborne geophysical surveys & 1,324.84sqkm of LiDAR topography was flown. Follow-up ground geophysical surveys resulted in a total of 37 surveys (514.64 Line-Km) being completed.

Initial NI 43-101 compliant resource defined at McAra (M&I Resource of 1,124,000lbs Co) was detailed in a Technical Report on Cobalt Exploration Assets in Canada dated as of February 5, 2021, with an effective date of October 31, 2020, prepared by SRK Consulting – G Cole PGeo (APGO#1416).

Idaho – Cobalt

BMR holds the Bonanza and East Fork properties located in the historic cobalt-copper-gold Blackbird mining district (Blackbird Mine from 1902-1963 produced 17Mt grading 0.7% Co, 1.4% Cu, and 1 g/t Au) located about 30 kilometers west of Salmon, Idaho. The Bonanza project is immediately adjacent to Jervois Global’s Idaho Cobalt Operations, the United States’ only operating primary cobalt mine. At Bonanza, there are seven mineralized sites within an area over three kilometers wide that extends along a gabbro dyke striking continuously for over six kilometers northward from Noranda’s historic Blackbird Cobalt/Copper mine. The showings on the project are Bonanza Copper Tunnels, Tinker’s Pride, Bonanza Copper #25, Indian Creek, Gray Copper, Blackrock #4 and Papoose #’s 1-4.

From 2018-2021, BMR’s Bonanza Exploration included 550 line-km of airborne magnetics and radiometrics followed up by surface exploration that included rock sampling, soil sampling, channel sampling of historic workings and 3.6km of time domain induced polarization geophysics.

The two properties cover 12 significant cobalt-copper prospects within the known mineralized zone. Both of the BMR Idaho cobalt belt properties host excellent high-grade discovery potential.

South Korea – Graphite

BMR has 100% ownership of the Guemam and Taehwa graphite exploration projects containing high-purity flake graphite deposits. Both assets are past-producing mines with existing local infrastructure and near-term production potential.

Nevada – Lithium

The company’s Amargosa lithium project is in the southern Basin & Range province and central Mojave Desert of Nevada. It is an early-stage exploration opportunity in a favorable region that hosts numerous lithium occurrences, including the Clayton Valley lithium deposit owned by Cypress Development Corp., as well as a major nearby lithium brine mine currently in production called the Silver Peak mine held by Albermarle Corp., one of the world’s largest lithium producers.

Market Opportunity

Near-term forecasts for the copper sector are extremely bullish, with stalwart Wall Street firms such as Goldman Sachs and Bank of America projecting record highs in the coming months. A combination of short-term supply deficits and long-term energy transition demand are expected to buck the downward pressures that have impacted copper prices in recent years.

Goldman in December 2022 forecast a 178K metric ton deficit in the copper market in 2023, causing the firm to raise its 12-month target to $11K/ton and its average price for calendar 2023 to $9,750/ton.

With China likely to continue accelerating efforts to restock depleted inventories in the wake of its COVID-19 reopening and a sustained push toward electrification around the globe placing a strain on supply, BMR is uniquely positioned to capitalize through the anticipated restart of operations at its Punitaqui copper mine.

Management Team

JMartin Kostuik is CEO and a Director of BMR. He brings to the company nearly three decades of diversified experience in the mining industry as a mining engineer and senior executive. Prior to joining BMR, Mr. Kostuik served as president and director of Arizona Gold Corporation and as CEO and director of Rupert Resources Limited. He built a broad base of experience in operations, engineering, exploration and capital projects with various companies including Luna Gold (Equinox), Barrick Gold Corporation, Taseko Mines Limited and DMC Mining Services. Mr. Kostuik earned his B.S. in Mining Engineering from Queen’s University and his M.B.A. from the University of Tennessee.

JMax Satel is the company’s CFO. He has over 18 years of experience as a successful natural resources-focused executive, most recently serving as EVP Corporate Development & Investor Relations for Arrow Exploration Corp., a TSX Venture- and AIM-listed oil & gas company with operations in Colombia and Canada. Prior to joining Arrow, Mr. Satel was principal and co-founder of Bordeaux Capital Inc., a Toronto-based advisory firm focused on the capital needs of companies across the natural resources sector, where he led and executed project financing advisory mandates involving global financial institutions and private equity funds. He earned a Bachelor of Commerce in Finance and Economics from the University of Toronto.

Jacob Willoughby is VP Corporate Development & Strategy for BMR. He brings to the company nearly 17 years of diversified experience in mining capital markets, including over eight years as a mining analyst covering exploration and development companies globally in both precious and base metals. Mr. Willoughby was most recently Vice President of Research and Analyst at Red Cloud Securities in Toronto. He spent two years as President and Director of Aldridge Minerals, a former Canadian based public exploration and development company with assets in Turkey and Papua New Guinea. Mr. Willoughby earned both a B.S. in Geology and a Masters in Business Administration from the University of Windsor.

FingerMotion Inc. (BTRMF), closed Friday's trading session at $0.1599, up 8.1867%, on 3,500 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0355/$1.05.

Recent News

• Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) - InvestorNewsBreaks - Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) Files NI 43-101 for Its Punitaqui Copper Mine, Highlights 2022 Accomplishments
• InvestorNewsBreaks - Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) Secures Approval of Environmental Permit for Mining at Punitaqui Complex
• Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) Committed to Strengthening, Benefitting Local Communities

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Psychedelics are hallucinogenic drugs that induce temporary alterations inmood, perception and mental processes in an individual wheningested. These drugs can occur naturally, such as psilocybin, orbe manufactured in a lab, such as LSD, which was first synthesizedby Albert Hoffman in 1938. Before psychedelics were classifiedunder Schedule 1 of the 1971 UN Convention on Psychotropic Drugs, the drugs were used to manage various symptoms and psychiatricissues. This classification was brought on mainly by the growinghostility of sociopolitical views regarding the use of drugs aswell as the covert and unethical use of said drugs. Substancesunder schedule 1 are said to have limited or no medicinal value andcannot be administered by registered practitioners without appropriate approval.These changing laws in different jurisdictions could help startupssuch as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) grow their footprint faster as enabling laws are passed andimplemented.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

• Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
• Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
• Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
• Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

• 32 million people in the U.S. have used psychedelics at least once
• 17% of all American adults between 21 and 64 have used psychedelics at least once
• $500 billion is spent in the U.S. every year on prescription drugs
• $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
• The anxiety disorder and depression treatment market is estimated at $16 billion
• $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Friday's trading session at $0.00605, up 6.1404%, on 8,451 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0031/$0.0676.

Recent News

• Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) - Challenges Facing European Psychedelics Industry
• Psychedelic-Assisted Therapy May Soon Gain Accreditation Standards
• Why Psychedelic Trips Cause Geometric Visual Effects

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Delaware Governor John Carney stated that he would permit two bills to become law without his signature to legalize cannabis possession and create a controlled adult-usemarket. This has since come to pass. Advocates were worried thatthe governor would override the proposals, as he did during theprevious session. He did, however, recently announced that he wouldlet HB 1 and HB 2 take effect without his active participation, which came as ahappy surprise to supporters. Carney, who had previously refrainedfrom commenting on his intentions regarding the marijuana reformproposals from Representative Ed Osienski (D), said that while hisopinions on the matter have not changed and he continues to believethat legalizing marijuana is not a positive move, he would nolonger oppose the reform. The newly enacted cannabis legalizationlaws could potentially create a market for businesses such as Advanced Container Technologies Inc. (OTC: ACTX), which supply indoor cultivation equipment to marijuana growers atcommercial scale.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.3, even for the day, on 54 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.073/$1.05.

Recent News

• Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - Delaware Governor Lets Cannabis Bills Become Law Sans His Signature
• 420 with CNW - Could Interstate Commerce Fix Cannabis Glut in Legal States
• 420 with CNW - Marijuana Retailers Celebrate 4/20 with Deals, Promotions

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

• Latest research shows that renewable energy from wind and solar ischeaper than electricity from coal, oil, or methane gas, dispellingany lingering doubts about their ability to compete on cost withtraditional fossil fuels

• The clean electricity sector is soaring, generating 39% of globalelectricity in 2022, a new record high; solar remains thefastest-growing electricity source for 18 consecutive years,growing by 24% in 2022

• Companies like GeoSolar appear poised for growth as greater demandfor cleaner energy creates opportunities for the sector andevidence shows that investing in renewables is not just good forthe environment, but also makes financial sense

A world powered by renewable sources once seemed like a distantdream, but it is gradually becoming a reality thanks to companieslike GeoSolar Technologies (“GST”), a Colorado-based climate technology company that seeks tolead Americans toward a more sustainable living.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

• Making a real planet-changing difference in reducing air pollution
• Eliminating or significantly reducing homeowners’ future utility bills
• Enjoying lifetime energy independence and protection from price escalation and energy shortages
• Eliminating greenhouse gas emissions from operation of home and daily life
• Increasing home value
• An integrated design for seamless operation of renewable energy systems
• Maintaining a significantly healthier living environment
• Leveraging existing renewable energy tax credits and electrification incentives
• Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News

• GeoSolar Technologies Inc. - GeoSolar Technologies Inc. Positioned to Gain from Shifting Tide as Renewable Electricity Sources Become Cheaper Than Traditional
• GeoSolar Technologies Inc. Set to Capitalize on Colorado’s Move to Promote Geothermal Energy Output
• QualityStocksNewsBreaks – GeoSolar Technologies Inc.’s SmartGreen(TM) Taking Decarbonizing Homes to the next Level

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

•Inflating air pollution levels are increasingly contributing torising respiratory infections and mortality rates around the world

•A key source of air pollution is derived from methane emissions,released by organic waste products

•RNG has emerged as a solution by which captured methane can beturned into a carbon neutral energy source

•EverGen Infrastructure has rapidly emerged as one of Canada’sleading RNG suppliers, with an ambitious long-term growth plan

India’s capital, New Delhi is a teeming metropolis and home toupwards of 25 million people; it is also one of the most pollutedcities in the world. In 2019, government authorities forecast thatover 1.67 million people had passed away across the country due toair pollution – largely a result of acute respiratory infections,including lung diseases, COPD, asthma add bronchial infections. InDelhi alone, it is estimated that air pollution could contribute toas many as 30,000 fatalities per annum and driving $36.8 billion ineconomic losses. Yet, Delhi’s air pollution conundrum is not solelydue to industrial activity and construction work, factors whichhave often been pinpointed as the primary contributors to India’spollution problem. Rather, a major factor contributing to Delhi’spollution woes is far closer to home – the cooking fuel used bymillions of households across the city (https://ibn.fm/trzox). At least 100 million people across India today depend on cowdung cakes and other biomass sources for cooking; methane, thechief emission released by organic waste has been found to benearly 25 times more potent than carbon dioxide in terms oftrapping heat within the earth’s atmosphere (https://ibn.fm/upCmA).Renewable natural gas (“RNG”), a form of refined biogas, hasemerged as a potential solution to global efforts towards arrestingrising methane emissions. When organic waste decomposes, itnaturally releases biogas – a greenhouse gas containing carbondioxide and methane, into the atmosphere. Companies such as EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), a British-Columbia based natural gas operator, have madecontaining methane emissions their core corporate mission. Througha combination of acquiring, developing, building, owning, andoperating a portfolio of RNG, waste-to-energy and relatedinfrastructure projects, EverGen has looked to combat climatechange and help the communities within which it operates to strivefor a more sustainable future.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2.28, off by 3.7975%, on 3,200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$2.94.

Recent News

• EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) - EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Boasts Unique Position Within RNG Space; Put Its Foot on the Pedal for Development Projects
• EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Targets Rising RNG Production Amidst Global Push Towards Renewable Energy Sources
• GreenEnergyBreaks - EverGen Infrastructure Corp.'s (TSX.V: EVGN) (OTCQX: EVGIF) Technologies Helping Reduce Dependence on Finite Fossil Fuels

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

•Lexaria recently completed its diabetes animal model study,DIAB-A22-1, an ambitious study that explored the potential of itspatented DehydraTECH(TM)-processed cannabidiol (“CBD”) for thetreatment of diabetes

•The study showed at least three primary positive outcomes,including weight loss and improved triglyceride and cholesterollevels, with lower doses of DehydraTECH-CBD achieving the mostoptimum outcome

•The success of this study inches Lexaria closer to capitalizing onthe potential of the diabetes drug market, estimated at $63.1billion in 2021

•It also points to the technology’s effectiveness, particularlyfollowing the success of the company’s most ambitious clinicalstudy, HYPER-H21-4, demonstrating the potential of DehydraTECH-CBDfor the treatment of hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. The company’spatented DehydraTECH(TM) drug delivery platform technologyincreases bioavailability, improving the way active pharmaceuticalingredients (“APIs”) enter the bloodstream by promoting moreeffective oral delivery, helping with speed of onset, and brainabsorption of active pharmaceutical ingredients. They recentlycompleted its diabetes animal model study DIAB-A22-1, an ambitiousstudy that explored the potential of its patentedDehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment ofdiabetes. The study produced at least three positive outcomes inwhat Lexaria’s management described as “encouraging,” furtherindicating many prospective benefits worthy of furtherinvestigation together down the line (https://cnw.fm/fw4H8).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.09, off by 4.2777%, on 19,596 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$3.60.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology
• InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards CRO Contract for Upcoming Hypertension Study
• InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.

EOR

In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.

FORWARD-LOOKING STATEMENTS

This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Friday's trading session at $0.05675, off by 1.8591%, on 71,164 volume. The average volume for the last 3 months is 2.172M and the stock's 52-week low/high is $0.0294/$0.239.

Recent News

• Laredo Oil Inc. (OTC: LRDC) - ESGBreaks - Laredo Oil Inc. (LRDC) Ideally Poised as Bullish 2023 Forecast Suggests Pricing Uptrend
• ESGBreaks - Laredo Oil Inc. (LRDC) Making Strategic Moves Toward Future Growth, Enhanced Presence in Public Financial Markets
• Laredo Oil Inc. (LRDC) Progressing Toward Drilling as 2023 Oil Demand Projected to Increase

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

• HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
• HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Friday's trading session at $2.26, up 11.8812%, on 58,469 volume. The average volume for the last 3 months is 1,300 and the stock's 52-week low/high is $1.12/$6.74.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Poised to Offer Timely Solution amid a 'Smoldering Public Health Crisis'
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients
• HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

Utopia VR

The QualityStocks Daily Newsletter would like to spotlight Utopia VR

Utopia VR is one of the world’s first ‘Metaverse-As-A-Service’ solutions for business. The company’s hosted and managed subscription software provides businesses a low barrier to entry, browser-based, device agnostic platform where they can manage their own private 3D metaverse meeting spaces. Users can host and attend Zoom-like virtual meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way.

Utopia VR has many technology and privacy advantages over solutions built on other metaverse marketplaces such as Horizon Worlds (META) or Decentraland. Utopia VR works on all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

Utopia VR is headquartered in Kelowna, B.C.

Products

Utopia VR’s The Metaverse for Everyone™ is a one-click, web-based, avatar-driven, mobile-friendly audio- and video-conferencing platform that utilizes innovative 3D web technology. Utopia VR’s virtual platform works on digital devices including PCs, mobile phones and VR headsets such as Oculus Quest or HTC Vive. No software or proprietary hardware is needed.

Users navigate through the various VRoom environments by using avatars. Users can walk, talk and sit – just like they do in the real world. A user’s avatar can be controlled with a computer keyboard, smartphone or virtual reality headsets. Text chat, voice and video is ever-present and used to communicate with others in the VRoom. For important meetings and presentations, users can also import audio, video, 2D art and images, animated 3D objects, PDF files and their favorite NFTs by simply dragging and dropping files into a VRoom or pasting a video link from supported media platforms.

Organizations that have an existing website can transition their digital assets, including text, images, video, PDFs, slideshows and more, to VRoom environments with a simple copy and paste. This will allow their customers and audiences to experience their brand in a whole new, immersive environment.
Utopia VR’s mobile app enables users to personalize their own 3D environments and then schedule business meetings or social meetups in seconds through a proprietary link management system. The app is available for iPhone and iPad users. The company’s website mirrors the app, which means users can access Utopia VR directly from a PC, laptop, tablet, or VR headset without downloading the app.

Market Outlook

Regarded as the next iteration of the internet, the metaverse is a virtual space where the physical and digital worlds coexist and interact, encompassing virtual reality, augmented reality, extended reality and mixed reality, as well as making use of artificial intelligence and other technologies.

Data consolidator Statista estimated that the global metaverse market size stood at $38.85 billion in 2021 and projected the market would grow to be worth $47.48 billion in 2022. From there, Statista forecasts the value of the metaverse market will explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period.

The metaverse could create $5 trillion in opportunity by 2030, according to McKinsey & Company.

Management Team

Stuart Gray, President, Co-Founder and director of Utopia VR, has been an officer and director for both private and publicly traded companies and has led public offerings for junior listed companies that have gone on to realize multibillion-dollar market valuations. He previously was a consultant and quarterbacked taking eXp World Holdings Inc. (NASDAQ: EXPI) public. eXp is a disruptive, no bricks and mortar, real estate brokerage firm with 85,000 agents worldwide using its virtual, software-based, metaverse platform for closing transactions, training and events.

Cory Braden, CTO and director of Utopia VR, is a forward-thinking strategic leader with over 20 years of experience in delivering software as a service. Recognized for a positive leadership style and excellent communication skills, he is well-versed in user experience, complex application architectures, cloud infrastructure and management of high-performance teams.

Terry Woloszyn, VP of Sales and Advisory at Utopia VR, brings vast technical and sales experience to the company. Before joining Utopia VR, he conceived and launched a data security startup and graduated from two startup accelerator programs. He has personally raised $20 million in equity venture funding.

Recent News

• Utopia VR - InvestorNewsBreaks – Genius Group Limited. (NYSE American: GNS) Announces Dual Listing, Commences Trading on Upstream in April
• InvestorNewsBreaks – Utopia VR Disrupting Future of Enterprise, Education and Corporate Remote Offerings with Distinct Metaverse Solution
• InvestorNewsBreaks – Utopia VR Launches MaaS Platform Amid Growing Demand for Virtual Offices, Hybrid Work Solutions